Company intelligence / Profile preview

Mentis AI

Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Mentis AI has deployed AI-driven solutions (e.g., chat-based companions and coaches) to support mental wellness, with intended integration into and augmentation of genetic testing services for psychedelic/cannabis use offered by Entheon; no clinical trial results as not a therapeutics company

Therapeutic areas: Psychiatry
Modalities: Non-pharmacological therapyDeviceDigital therapy
Industry: Digital Health Medical Devices

Partnerships

Letter of intent with Entheon Biomedical Corp. (relationship terminated in March 2025)

Beyond the preview

Go deeper on Mentis AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mentis AI.

Explore the full profile